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Background: Induction of labour is a common obstetric procedure. At present, different methods are used for
induction of labour in women with an unfavourable cervix. Recently, we showed that in term women with an
unfavorable cervix the use of a Foley catheter in comparison with vaginal Prostaglandin E2 gel, results in a
comparable vaginal delivery rate. A meta-analysis on the subject indicated lower rates of hyperstimulation, and
probably as a sequel fewer cases of postpartum haemorrhage. Misoprostol (PgE1) is another type of prostaglandin
frequently used for labour induction, recommended by the international federation of gynaecology and obstetrics
(FIGO). Misoprostol can be administered by vaginal, rectal and oral route. There is evidence that oral administration
results in less asphyxia and hyperstimulation than vaginal administration. At present, valid comparisons between
oral misoprostol and Foley catheter are lacking. Therefore, we propose a randomised controlled trial comparing
Foley catheter to oral misoprostol in order to assess safety and cost-effectiveness.
Methods/Design: We plan a multicentre, randomised, controlled, open-label clinical trial among term pregnant
women with a vital singleton in cephalic presentation, unfavorable cervix, intact membranes and an indication for
induction of labour. After informed consent, women will be randomly allocated by a webbased randomisation
system to transcervical Foley catheter or oral misoprostol (50 mcg every 4 hours). The primary outcome will be a
composite of complications of uterine hyperstimulation, i.e. post partum haemorrhage and asphyxia. Secondary
outcomes are mode of delivery, maternal and neonatal morbidity, costs and women’s preference. Serious adverse
events such as severe maternal or neonatal morbitity or mortality will be monitored and reported to an
independent data safety monitory board. With a sample size of 1860 women we will be able to demonstrate a 5%
non-inferiority of the Foley catheter as compared to misoprostol for the composite outcome.
Discussion: Worldwide, various methods are being used for labour induction. Results of the proposed trial will
contribute to the answer which method of induction of labour is most safe, cost-effective, and patient friendly and
will help to construct evidence based guidelines.
Trial registration: The Netherlands Trial Register NTR3466
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Induction of labour is a commonly practiced obstetric
intervention designed to artificially initiate the process of
effacement of the cervix, dilatation (cervical ripening),
uterine contractions (often after augmentation with oxyto-
cin) and eventually delivery of the baby. Common indica-
tions for induction of labour are post-term pregnancy,
hypertensive disorders, diabetes in pregnancy, cholestasis,
decreased physical activity of the fetus and prelabour rup-
ture of membranes. Induction of labour with an unfavor-
able cervix is associated with prolonged labour compared
to spontaneous onset of labour or induction of labour with
a favorable cervix. Also an increase in instrumental deliv-
eries and a higher rate of caesarean sections are seen [1-3].
To increase the success of labour induction it is essential
to achieve cervical ripening in women with an unfavorable
cervix. Misoprostol has been widely studied as an agent
for induction of labour. There are currently two Cochrane
reviews focusing on the use of both oral and vaginal miso-
prostol [4,5]. These systematic reviews conclude that mi-
soprostol is an effective and safe induction agent. Oral
misoprostol is preferred to vaginal administration for as it
shows lower rates of uterine hyperstimulation and adverse
neonatal outcome [4,5]. Although not licensed for induc-
tion of labour, misoprostol is recommended by several
guidelines. The British Royal College of Obstetricians and
Gynaecologists (RCOG), as well as the World Health
Organization (WHO), recommend the use of misoprostol
tablets, based on cost-effectiveness. In the Dutch Society
of Gynaecology and Obstetrics (NVOG) guideline for in-
duction of labor, misoprostol is included and reported to
be effective and safe [6-8]. Another method for induction
of labour is the transcervical Foley catheter. We recently
showed (PROBAAT trial) that induction of labour with a
Foley catheter is as effective as induction with intravaginal
prostaglandin E2 gel, with fewer maternal and neonatal
side-effects [9]. The caesarean section rate was comparable
and in the meta-analysis of three trials on the subject, the
Foley catheter revealed a lower rate of hyperstimulation,
resulting in fewer cases of asphyxia and less post partum
haemorrhage. Consequently, the transcervical Foley cath-
eter was recommended for induction of labour in women
with an unfavorable cervix at term [9]. The Foley catheter
is reported to have similar success rates as induction of
labour with misoprostol (vaginal and oral), and is associ-
ated with less uterine hyperstimulation with and without
fetal heart rate (FHR) changes and a comparable caesarean
section rate [10-14]. As prostaglandins in general have
been shown to cause an increased incidence of hyper-
stimulation, we expect a decreased blood flow of the pla-
centa and consequently an increased the risk of asphyxia.
In addition, hyperstimulation might lead to uterine muscle
fatigue and thereby increase the risk for post partum haem-
orrhage. However, randomised controlled trials currentlyavailable are underpowered to investigate these estimators.
In view of the scarce evidence on the subject, we propose
a adequately-powered randomised controlled trial com-
paring induction of labour with a Foley catheter to induc-
tion of labour with oral misoprostol in women with an
unfavorable cervix at term. In this trial the safety, cost-
effectiveness and patient preference will be evaluated.
Methods/Design
Aims
The aim of this study is to assess the safety and cost-
effectiveness of induction of labour with a transcervical
Foley catheter as compared to induction with oral miso-
prostol in term pregnant women with an unfavourable
cervix.
Participants/eligibility criteria
Term pregnant women will be informed about the trial at
the moment the decision is made to induce labour. Eligible
are women ≥ 18 years with a gestational age ≥37 weeks
with a vital singleton in cephalic presentation, intact mem-
branes and an unfavourable cervix (Bishop score <6). Ex-
clusion criteria are hypersensitivity for any of the products
used, a history of caesarean section, placenta praevia, or
lethal congenital anomalies.
Procedures, recruitment, randomisation, collection of
baseline data
This trial will be a multicentre, open-label, randomised
controlled trial. The study will be performed within the
Dutch Consortium for Studies in Women’s Health and
Reproductivity (www.studies-obsgyn.nl). Participating hos-
pitals can be district, teaching or academic hospitals. Be-
fore entry into the study, women will be informed about
the aims, methods, reasonably anticipated benefits and po-
tential hazards of the study. This will generally be at least
1 day before actual admission for induction. They will be
informed that their participation is voluntary and that they
may withdraw consent for participation at any time during
the study. Choosing not to participate will not affect
care. In each centre an independent physician will be
available for more detailed information for both patients
and colleagues if desired. After counselling, written in-
formed consent will be obtained. The consent form
must be signed before performing of any study-related
activity. Randomisation will be performed web-based
using ALEA. After entering patient initials, confirming
inclusion criteria and absence of exclusion criteria, ran-
domisation will be performed realtime based on an al-
gorithm. We will use fixed block sizes of 2 and 4 and
stratify for centre and parity. As there is no prespecified
randomisation list, it will be hardly possible for anyone
to know the next allocation. Randomisation will take
place after evaluation of the fetal condition by CTG, just
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cated in a 1:1 ratio to induction with a Foley catheter or
oral misoprostol. There will be no blinding of patients
and caregivers, as this is not feasible with these two
treatment methods. Baseline demographic, obstetric
and medical histories, and details of delivery and health
care received till the time of discharge will be recorded
for all women. Data will be entered into an electronic
case-record form (Oracle Clinicle version 4.5.3) access-
ible through our study website with a personal login
http://www.studies-obsgyn.nl/probaat2. All changes made
in this electronic case-record form will be captured in an
audit trial. In Oracle Clinicle checks will be programmed
to identify errors. All electronic case-record forms will be
checked for consistency and to correct errors.
Interventions
At the start of the study, each centre will be instructed
in a brief presentation and practical training. When
needed, a local research nurse is available during the in-
clusion period to advise the staff on use of the Foley
catheter and/or oral misoprostol.
Induction with a transcervical Foley catheter
A 16 or 18 F Foley catheter will be introduced into the
cervix and the balloon is filled with 30 cc of 0.9% NaCl
or water. The Foley catheter can be placed digitally or
using a speculum according to preference of the treating
physician. No recommendations regarding disinfection
will be given as there is no evidence for the best method.
The external end of the Foley catheter will be tapped to
the thigh without giving traction. Foley catheter location
after placement can be evaluated digitally and/or by
ultrasound. Women will be instructed to observe one
hour of bed rest after every newly placed Foley catheter,
while fetal condition and uterine activity will be moni-
tored. Women will be examined every 12 hours if the
transcervical Foley catheter does not detach spontan-
eously. When the Bishop score remains <6; the location
of the Foley catheter will be evaluated and a new Foley
catheter will be placed after 24 of 48 our depending on
the preference of the participating centre.
Induction with oral misoprostol
Patients in the misoprostol group will be treated according
to the protocol used in the study of Gemund et al. [15].
Misoprostol will be administered every four hours with a
maximum of three times a day for 4 days. For this study
the protocol was adjusted to use of oral misoprostol.
Women in the misoprostol group will receive 50 mcg mi-
soprostol capsules. Since misoprostol 50 mcg tablets are
not on the market and misoprostol as a raw material is not
available, the 50 mcg tablets are made from the originally
Cytotec 200 mcg, Searle, Maarsen, The Netherlands by theLeiden University Medical Centre pharmacy. 200 mcg
Cytotec tablets are pulverized with a cube mixer. Capsules
are prepared from portions of the powder mixture.
Amount of powder mixture is optionally supplemented
with microcrystalline cellulose to achieve volume for
100 capsules. Each capsule contains between 47.5 and
52.5 mcg misoprostol. High-performance liquid chro-
matography shows the standard retention time and
sample are the same (within 2.5%). Women will be
instructed to observe one hour of bed rest after every
dose of misoprostol, while fetal condition and uterine
activity will be monitored. When there will be 3 or more
contractions in 10 minutes while the Bishop score is still
<6 or when the fetal heart rate is not reassuring the next
misoprostol dose will be withheld. Amniotomy and oxy-
tocin infusion can be started at any moment of the day
when the Bishop score is ≥ 6, and at least 4 hours after
the last dose of misoprostol. Women will be treated for
a maximum of 4 days with Foley catheter or oral miso-
prostol. If after 4 days the cervix remains unfavorable,
the induction is considered to be failed and further
management will be decided individually by the treating
physician. The number of women needing more than
48 hours of induction is expected to be very low.
Outcome measures
The primary endpoint will be a composite outcome of neo-
natal asphyxia (defined as a neonatal pH ≤ 7.05 and/or
5 minute Apgar score <7) and/or post partum haemor-
rhage (defined as an estimated blood loss of ≥1000 cc
ascertained over 24 h post partum). We have chosen this
combined outcome as both conditions are thought to be a
result of hyperstimulation.
Secondary endpoints:
 Mode of delivery (Caesarean section, vaginal
operative delivery, spontaneous delivery) and the
reason for operative delivery, i.e. suspected fetal
distress and/or failure to progress.
 Induction to delivery time,
 Use of analgetics
 Oxytocin use
 Number of misoprostol gifts/Foley catheters used.
 Number of vaginal examinations
 Maternal morbidity○ Post partum blood transfusion and number of
packed cells
○ Tachysystole (defined as more than five
contractions in ten minutes over a minimal period
of two times ten minutes)
○ Hyperstimulation (defined as tachysystole with
FHR changes (defined as a non reassuring CTG by
treating physician))
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lasting longer than two minutes with FHR changes)
○ Uterine rupture (occurrence of clinical
symptoms (abdominal pain, abnormal fetal heart
rate pattern, acute loss of contractions, vaginal
blood loss) leading to an emergency caesarean
delivery, at which the presumed diagnosis of
uterine rupture was confirmed; or peripartum
hysterectomy or laparotomy for uterine rupture
after vaginal birth)
○ Uterine scar dehiscence (separation of a pre-
existing scar that does not disrupt the uterine
serosa as seen during caesarean section, without
clinical consequences)
○ Maternal infection during labour (defined as
fever, i.e. temperature ≥ 37.8°C, or fetal tachycardia
AND start of antibiotics)
○ Maternal infection within one week post
partum (defined as fever, i.e. temperature ≥ 37.8°C,
AND start of antibiotics)
○ Start of intravenous antibiotics
○ Endo(myo)metritis or urinary tract infection
within one week post partum (proven positive
vaginal/urine culture)
○ Other medication used during labour such as
tocolytics.
 Neonatal parameters consisting of:
○ Fetal tachycardia (sustained fetal heart rate
above 160 beats per minute)
○ Gender
○Weight at birth
○ Meconium-stained liquor
○ Apgar scores <7 at 1 minute
○ Admission to the neonatal ward/NICU and its
reason (suspected infection, infection proven by
positive culture, other reason admission to
medium or intensive care).
An economic analysis will be conducted alongside the
PROBAAT-II trial. In order to do so, resource use in dif-
ferent phases of delivery will be collected in the electronic
case-record form (eCRF). To our knowledge, no validated
questionnaires on women’s preference of induction of
labour method are available. Therefore women’s prefer-
ence for the method of induction will be evaluated by a
post partum questionnaire developed for this study, based
on a validated questionnaire by Wijma et al. This ques-
tionnaire was developed to assess women’s experience of
labour [16].
Follow up of women and infants
Details of admission of women and newborns will be
recorded as will maternal and neonatal complications.
Long term follow-up is not part of the current study.Analysis
This trial is designed as a non-inferiority trial. Primary
analysis will be by intention-to-treat. In a comparative
trial, where the aim is to decide if two treatments will be
different, an intention-to-treat analysis is generally conser-
vative: the inclusion of protocol violators and withdrawals
will usually make the results from the two treatment
groups more similar. However, for a non inferiority trial
this effect is no longer conservative: any blurring of the
difference between the treatment groups will increase the
chance of declaring non inferiority [17]. We will therefore
also perform a per protocol analysis. Relative risks and
95% confidence intervals will be calculated for the relevant
outcome measures. We will additionally adjust for the
stratified randomization when calculating the relative risk.
Differences between categorical variables will be tested
with the Chi-square test, or if the expected cell count is
below 5 with the Fisher’s exact test. Non-normally dis-
tributed continuous variables will be tested with the
Mann–Whitney U test. Time to delivery will be assessed
using Kaplan-Meier analysis. For the economic analysis
we plan a cost-minimisation procedure, as we designed
a non-inferior trial and expect no differences in out-
comes. Resource uses are multiplied by their specific
costs, which are estimated according to recent guide-
lines on costing health care services. When a relevant
differences in outcomes will be observed, we will per-
form a cost-effectiveness analysis, in which we calculate
the additional cost per prevented case of fluxus or as-
phyxia and the cost per prevented Caesarean section.
Mean resource use and costs are compared between
both arms, if any difference of interest in primary and/
or secondary outcomes occurs a cost-effectiveness ana-
lysis will be performed. Using an interaction term we
will assess whether the difference in effect between mi-
soprostol and Foley catheter is consisted in nulliparous
and multiparous women.
Sample size
To calculate an adequate sample size we searched the lit-
erature for comparisons between oral misoprostol and
Foley catheter. There is only one study which directly
compared induction of labour with oral misoprostol and
Foley catheter. This study does not report on our primary
outcome measures which makes it insufficient to use for
our power calculation [10]. A few studies reported on a
comparison of vaginal misoprostol and prostaglandin E2,
but different dosages were used and from the reported
outcome parameters it was not possible to calculate the
composite outcome we use [6]. Therefore we used data
from the PROBAAT trial, comparing prostaglandin E2
(prostin) with Foley catheter [9]. In the Probaat trial the
incidence of the composite outcome of pH ≤ 7.05 and/or
an Apgar < 7 at 5 minutes (at least one known) and/or
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Foley catheter was used and 16.4% when Prostaglandin E2
gel was used. We expect the incidence of the composite
outcome to be lower when using oral misoprostol than
when using prostaglandin E2 but slightly higher than
when a Foley catheter is used [5]. We expect that about
25% of umbilical cord pH’s will be missing, while the
5 minute Apgar will be complete in nearly all cases. So, if
the umbilical artery pH data will be missing, neonatal out-
come will be classified as abnormal if the 5 minute Apgar
will be <7 and as normal if the Apgar was ≥ 7. With a
power of 80% (1-β) and a one-sided 0.05 risk of type I
error (α), we need 1860 participants (930 per group) to
demonstrate non-inferiority, i.e. that the absolute differ-
ence in the composite outcome will be less than 5% in the
misoprostol group compared to the Foley catheter group,
when assuming that the composite outcome was 12.7% in
the Foley catheter group and 13.7% in the misoprostol
group and an 5% exclusion rate from the per protocol ana-
lysis. This sample size will also give us more than 80%
power to demonstrate non-inferiority, i.e. less than 5% in-
crease in the proportion of caesarean sections when using
misoprostol compared to Foley catheter, assuming 23%
caesarean sections in both groups [9]. We used NQuery
Advisor 7.0, with the two group test of equivalence in pro-
portion (NQueryAdvisor; Machin 1987) to calculate the
sample size.
Monitoring
An independent data and safety monitoring board (DSMB)
will be established prior to the start of the trial. All the
serious adverse events (SAE’s) (intra uterine fetal death
(IUFD), uterine rupture, severe maternal and neonatal
morbidity such as IC/NICU admission and related events
such as placental abruption directly after insertion of Foley
catheter) will be reported within 48 hours to the CCMO
(central commission human related research). All SAEs
will be reported to the DSMB at 300 and 600 inclusions
when the interim analysis will take place, or when in total
5 SAEs are reported, whichever comes first. Prior to the
start of the trial the DSMB defined criteria to terminate the
trial prematurely. The DSMB will perform 2 interim ana-
lyses: after recruitment of 300 and 600 patients. These in-
terim analyses will be conducted independently of the
research group, and will take into account safety (infection,
asphyxia, haemorrhage) as well as efficacy. The study will
be terminated prematurely for efficacy according to the
Haybittle rule when there is a difference with P <0.001.
Ethical considerations
This study has been approved by the National Central
Committee on Research involving Human Subjects
(CCMO - NL 35278.018.11.), by the ethics committee of
the Academical Medical Centre (Ref. No. 2011_010#B20-12219). The boards of directors of all participating hospi-
tals approved local execution of the study.
Discussion
In Western countries, labour is induced in 20-30% of all
pregnant women for various reasons. Until now different
methods for labour induction are used. In literature
contradictory results are reported regarding efficacy and
safety of the induction methods. The outcome of our re-
cent study which compared prostaglandin gel to a Foley
catheter was that the Foley catheter showed fewer ma-
ternal and neonatal side-effects and was as effective as
prostaglandin gel [9]. Another widely used method of
labour induction is the administration of misoprostol.
Misoprostol is recommended by several (inter)national
guidelines, based on cost-effectiveness [6,8]. However,
randomised controlled trials are underpowered to inves-
tigate the estimators of interest. Therefore we will com-
pare in an adequately powered randomised open-label
controlled trial induction of labour at term with a Foley
catheter to oral misoprostol. Taking into account the
possible risks, costs and women’s preferences; this study
could assess the safest, most cost-effective and patient
friendliest way of inducing labour with an unfavorable
cervix. Eventually this study could contribute to achieve
consensus in the guidelines, thereby improving the care
for over 20% of all the pregnant women in western
countries from who labour will be induced.
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